Santiago Ponce-Aix

Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial

Kazuhiko Nakagawa, Edward B. Garon, Takashi Seto et al. · The Lancet Oncology · 2019 · 613 citations · Full text

Medicine, Oncology, Pharmacology +12

Association of<i>EGFR</i>L858R Mutation in Circulating Free DNA With Survival in the EURTAC Trial

Niki Karachaliou, Clara Mayo-de las Casas, Cristina Queralt et al. · JAMA Oncology · 2015 · 238 citations · Full text

Medicine, Molecular Biology, Oncology +17

Analysis of Expression of Programmed Cell Death 1 Ligand 1 (PD-L1) in Malignant Pleural Mesothelioma (MPM)

S. Cedrés, Santiago Ponce-Aix, Jon Zugazagoitia et al. · PLoS ONE · 2015 · 219 citations · Full text

Medicine, Cancer Biology, Oncology +16

Clinical utility of plasma-based digital next-generation sequencing in patients with advance-stage lung adenocarcinomas with insufficient tumor samples for tissue genotyping

J. Zugazagoitia, Inmaculada Ramos, José Trigo et al. · Annals of Oncology · 2018 · 87 citations · Full text

Medicine, Molecular Medicine, Oncology +17

Immunotherapeutic maintenance treatment with toll-like receptor 9 agonist lefitolimod in patients with extensive-stage small-cell lung cancer: results from the exploratory, controlled, randomized, international phase II IMPULSE study

Michael Thomas, Santiago Ponce-Aix, Alejandro Navarro et al. · Annals of Oncology · 2018 · 81 citations · Full text

Medicine, Oncology, Pharmacology +15